

Supplemental material

European Stroke Organisation (ESO) – European Society for Minimally Invasive Neurological Therapy (ESMINT) expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischaemic stroke and anterior circulation large vessel occlusion

Supplemental Table 1: Intellectual and financial disclosures of the module working group members

Author	Discipline and affiliation	Intellectual and financial disclosures
Guillaume Turc	Neurologist, GHU Paris Psychiatrie et Neurosciences, Sainte-Anne hospital, Université de Paris, INSERM U1266, FHU NeuroVasc, Paris, France	Intellectual disclosures: - Chairman of the ESO Guideline board - Co-chairman of the 2019 ESO-ESMINT Guidelines on mechanical thrombectomy - Co-chairman of the 2021 ESO Guidelines on intravenous thrombolysis Financial disclosures: - Lecturing fees for Guerbet France
Georgios Tsivgoulis	Neurologist, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece &	Intellectual disclosures: - Consulting Editor for Stroke - Associate Editor for Therapeutics advances in Neurological Disorders Financial disclosures:

	Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA	<p>- Participation in advisory meetings & satellite symposia for Boehringer-Ingelheim; Novartis, Sanofi, Biogen, Genesis Pharma, Teva, Merck-Serono, Bayer, Daichii-Sankyo, Allergan, Specifar, Actavis, Shire, Medtronic, CSL Behring, Abbvie, Ipsen, Abbott, Takeda, Roche.</p> <p>- Unrestricted research grants from Novartis, Genesis Pharma, Teva, Shire, Merck-Serono, Medtronic, Boehringer-Ingelheim, Allergan, Amicus, Abbvie, Ipsen, Abbott, Sanofi, Bayer, Roche.</p>
Heinrich J. Audebert	Neurologist, Klinik und Hochschulambulanz für Neurologie, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin & Center for Stroke Research Berlin, Berlin, Germany	<p>Intellectual disclosures: none</p> <p>Financial disclosures:</p> <p>- Received institutional funding for the B_PROUD study and the underlying B-SPATIAL Registry by the Federal Ministry of Education and Research (BMBF) via the Center for Stroke Research Berlin and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) as well as by the DFG within the Excellence Cluster NEUROCORE.</p> <p>- Speaker honoraria from Lundbeck and Boehringer Ingelheim (both developing / producing drugs for acute stroke treatment) and Bayer Vital, Bristol- Myers Squibb, Novo Nordisk, Pfizer, and from Sanofi outside the submitted work.</p> <p>- Principal investigator of the INSPiRE-TMS project, co-funded by Pfizer</p> <p>- The author's employer, the Charité Universitätsmedizin Berlin, receives a 0.5% institutional share of Stroke Emergency Mobiles (STEMO) turnover from the STEMO manufacturer (Meytec GmbH) arising from previous public funding within the Berlin Zukunftsfonds. The author doesn't have access to this money neither in person nor related to his working groups.</p>
Hieronymus Boogaarts	Neurosurgeon, department of neurosurgery, Radboud University Medical Center, Nijmegen, The Netherlands	<p>Intellectual disclosures: none</p> <p>Financial disclosures: Consultant for Stryker Neurovascular; fees paid to department of Neurosurgery Radboud University Medical Center Nijmegen.</p>
Pervinder Bhogal	Interventional Neuroradiologist,	Intellectual disclosures: none

	Department of Interventional Neuroradiology, Royal London hospital, Barts NHS Trust, London, UK	Financial disclosures: Consulting agreements with Phenox, Balt, Brainomix, Neurovasc Technologies, J&J/Cerenovus, Perfuze, Vesalio. UK CI Neva 1 registry.
Gian Marco De Marchis	Neurologist, Neurology and Stroke Center; Department of Clinical Research, University Hospital of Basel, University of Basel, Basel, Switzerland	Intellectual disclosures: Co-Investigator in an advisory role in the TWIST trial of tenecteplase (NCT03181360). Sponsor of trial is University Hospital of North Norway in Tromsø. Boehringer-Ingelheim will reimburse the sponsor for the costs of tenecteplase in the trial. Steering committee member of the PACIFIC-Stroke trial (NCT04304508) sponsored by BAYER. Editorial Board of Stroke. Industry support is devolved to a research fund of the University Hospital of Basel. Financial disclosures: Support from the Swiss National Science Foundation ; Spezialprogramm Nachwuchsförderung Klinische Forschung, University of Basel; Science Funds (Wissenschaftspool) of the University Hospital Basel; Swiss Heart Foundation; Bangerter-Rhyner-Stiftung; Swisslife Jubiläumsstiftung for Medical Research; Swiss Neurological Society; Fondazione Dr Ettore Balli; De Quervain research grant; Thermo Fisher GmbH; travel honoraria by Bayer and BMS/Pfizer; speaker honoraria by Bayer and Medtronic. Industry support is devolved to a research fund of the University Hospital of Basel.
Ana Catarina Fonseca	Neurologist, Department of Neurosciences and Mental Health (Neurology), Hospital Santa Maria-CHLN, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal	Intellectual disclosures: - Has received research grants from the "The foundation for science and technology" and from the "Portuguese Stroke Society". Financial disclosures: - Speaker honoraria from Daiichi Sankyo
Pooja Khatri	Department of Neurology, University of Cincinnati, Cincinnati, OH, USA	Intellectual disclosures: - None

		<p>Financial disclosures:</p> <p>Pooja Khatri's department receives funding from Cerenovus (investigator-initiated grant, ENDOLOW trial), Lumosa (advisor), and Diamedica (advisor); she also receives compensation from Bayer (National Leader, Pacific Stroke trial) and Basking Biosciences (advisor).</p>
Mikaël Mazighi	<p>Neurologist, Departement of neurology, Lariboisière hospital-APHP-Nord, & interventional neuroradiology, Fondation A. Rothschild hospital, Université de Paris, INSERM U1148, FHU NeuroVasc, Paris, France</p>	<p>Intellectual disclosures:</p> <ul style="list-style-type: none"> - Scientific coordinator of the BOOSTER consortium funded by the French national research agency. <p>Financial disclosures:</p> <ul style="list-style-type: none"> - Consulting fees from Boehringer Ingelheim, Amgen, Air liquide, and Acticor Biotech
Natalia Pérez de la Ossa	<p>Neurologist, Germans Trias i Pujol, Hospital, Badalona, Spain</p>	<p>Intellectual disclosures: none</p> <ul style="list-style-type: none"> - Director of the Catalan Stroke Program - Principal investigator of the RACECAT trial, funded by Medtronic - Sponsored by Redes Temáticas de Investigación Cooperativa (RETICS-INVICTUS-PLUS RD0016/0019/0020) and by the project SLT008/18/0007, PERIS programme from the Catalan Health Government. <p>Financial disclosures: none</p>
Peter D. Schellinger	<p>Neurologist, Departments of Neurology and Neurogeriatrics, John Wesling Medical Center Minden, UK RUB, Germany</p>	<p>Intellectual disclosures:</p> <ul style="list-style-type: none"> - Editorial Board Journal of Stroke <p>Financial disclosures:</p> <ul style="list-style-type: none"> - Participation in advisory board meetings & satellite symposia for Boehringer-Ingelheim; Astra Zeneca, AbbVie, BMS/Pfizer, Daichii-Sankyo. - Consultant for Astra Zeneca and Boehringer Ingelheim
Daniel Strbian	<p>Neurologist, Department of Neurology, Helsinki</p>	<p>Intellectual disclosures: none</p>

	University Hospital and University of Helsinki, Helsinki, Finland	Financial disclosures: - Research support from Boehringer Ingelheim - Consulting fees from Boehringer Ingelheim, Bayer, Pfizer and Bristol-Myers Squibb
Danilo Toni	Neurologist. Department of Human Neurosciences, University La Sapienza, Rome, Italy	Intellectual disclosure: none Financial disclosures: advisory board and speaker's honoraria for: Abbott, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Pfizer.
Philip White	Interventional & Diagnostic Neuroradiologist, Translational and Clinical Research Institute, Newcastle University, UK & Newcastle upon Tyne Hospitals NHS Foundation Trust, UK	Intellectual disclosures: - Associate Editor for the Journal of Neurointerventional Surgery - DMSB member MR CLEAN No-IV, TENSION, PROTECT-U - Chairperson UK Neurointerventional Group, Chair ESMINT Education Committee Financial disclosures: - Educational consultancy work for Microvention Unrestricted institutional research grants from Stryker, Medtronic, Penumbra & Microvention
William Whiteley	Neurologist, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom Senior Research Fellow, Nuffield Department of Population Health	Intellectual disclosures: - Has received research funding for the Chief Scientist's Office, the UK Medical Research Council, the Stroke Association, the Alzheimer's Society, Chest Heart and Stroke Association. Acts as an expert witness to the court in cases related to stroke. - Is on the data monitoring committee of the TEMPO-2 trial and therefore demitted from discussions in section 9.3. - Advisory board for Bayer, fees to institution Financial disclosures: none
Andrea Zini	Neurologist, Head of Department of Neurology and Stroke Center, Maggiore Hospital,	Intellectual disclosures: -Principal Investigator for project RF-2019-12370834 "FibER: Fibrinogen replacement to prevent intracranial haemorrhage in ischemic stroke patients after thrombolysis: a

	IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy	<p>pilot RCT (sponsored by Grant of the Italian Health Ministry), EudraCT 2020-005242-41.</p> <p>-Member of editorial board of Journal of Clinical Neuroscience and of Frontiers in Neurology (Stroke)</p> <p>Financial disclosures:</p> <ul style="list-style-type: none"> - Advisory board for Stryker, Alexion, Daiichi-Sankio - Speaker fees for Cerenovus - Consulting fees from Boehringer-Ingelheim
Wim van Zwam	Interventional Radiologist, Department of Radiology and Nuclear Medicine, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands	<p>Intellectual disclosures:</p> <p>Principle Investigator of MrClean-Late trial. Co-investigator of MrClean_NoIV trial. DSMB chair Solonda trial. DSMB chair InExtremis trials. DSMB chair WE-TRUST trial.</p> <p>Financial disclosures:</p> <p>Speaker fees from Cerenovus, Stryker and NicoLab, all paid to Institution</p>
Jens Fiehler	Interventional Neuroradiologist, Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany	<p>Intellectual disclosures:</p> <p>President of ESMINT, member of other scientific societies (DGNR, ESNR, DSG, ESO, CIRSE, DeGIR, DRG)</p> <p>Associate Editor for the Journal of Neurointerventional Surgery</p> <p>Financial disclosures:</p> <p>German Ministry of Science and Education (BMBF), German Ministry of Economy and Innovation (BMWi), German Research Foundation (DFG), European Union (EU), Hamburgische Investitions- und Förderbank (IFB), Medtronic, Microvention, Route92, Stryker. <i>Consultant for:</i> Acandis, Cerenovus, Medtronic, Microvention, Penumbra, Phenox, Stryker. <i>Stock holder:</i> Tegus Medical</p>

Supplemental Table 2: Results of the votes for the Expert Consensus Statements

For patients directly admitted to a thrombectomy-capable centre within 4.5 hours of symptom recognition after wake-up ischaemic stroke caused by anterior circulation large vessel occlusion, we suggest intravenous thrombolysis plus mechanical thrombectomy over mechanical thrombectomy alone in selected patients.	14/18 (78%) writing group member agree.
For patients admitted to a non-thrombectomy capable centre within 4.5 hours of symptom recognition after wake-up ischaemic stroke caused by anterior circulation large vessel occlusion, we suggest intravenous thrombolysis plus mechanical thrombectomy over mechanical thrombectomy alone in selected patients.	16/18 (89%) writing group member agree.